No Data
Zhaoke Ophthalmology-B (06622.HK): Latanoprost eye drops, Tafluprost eye drops, and Tafluprost nasal drops have been approved for marketing by the National Medical Products Administration.
On December 9, Gelonghui reported that Zhaoke Ophthalmology-B (06622.HK) announced that following the approval for marketing of Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, the company's glaucoma product portfolio has recently added three more pharmaceuticals (Latanoprost Eye Drops, Travoprost Eye Drops, and Travoprost Timolol Eye Drops) that have been approved for listing by the National Medical Products Administration ("NMPA"), equivalent to passing the consistency evaluation of generic drugs. These pharmaceuticals are all produced by the company. Together with Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, they constitute a comprehensive glaucoma product portfolio for managing intraocular pressure. The company believes its products...
Express News | Zhaoke Ophthalmology - Marketing Authorizations Obtained From Nmpa for Latanoprost Eye Drop, Travoprost Eye Drop, and Travoprost Timolol Eye Drop
Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results
China Medical Ophthalmology-B (06622.HK): The positive top-line results of the two-year China Phase III clinical trial (CHINA CHAMP) for NVK002, used to treat deepening myopia in children.
Oct 23, Geelong Health | Medigen Eye Care-B (06622.HK) announced that the topline results of the two-year Phase III clinical trial ("China CHAMP") of NVK002 (one of the company's core products) were released. After two years of treatment, the analysis of this study shows that the NVK002 eye drop group (0.01% and 0.02% doses) had statistically significant differences in the main efficacy indicators compared to the placebo group, with NVK002 eye drop group being superior to the placebo group and showing dose dependence. Both doses of NVK002 demonstrated good safety and patient compliance.
Zhaoke Ophthalmology Completes Last Patient Visit for Trial of Macular Degeneration Drug
Chow's Ophthalmology-B (06622.HK): The final visit of the last patient in the TAB014 Phase III clinical trial was completed in China.
Glory9thdayTheMeanwhile,ZodiacEye-C(06622.HK)announced that TAB014(oneofthecompany'scorecandidateproperties)hascompletedthelastvisitforthelastpatientinPhaseIIIclinicaltrialfortreatingwet(neovascular)age-relatedmaculardegeneration('wAMD')onSeptember20,2024.Accordingtothedisclosure,TAB014PhaseIIIclinicaltrialisrandomized,double-blind,andnon-inferioritystudy.Theprimaryobjectiveofthestudyistoevaluate the best correction of the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at week 52.
No Data
